e4fd984y

Property	Value
?:abstract	BACKGROUND: Studies have shown worse outcomes in patients with comorbid ischemic stroke (IS) and coronavirus disease 2019 (COVID-19), but have had small sample sizes. METHODS: We retrospectively identified patients in the Vizient Clinical Data Base® with IS as a discharge diagnosis. The study outcomes were in-hospital death and favorable discharge (home or acute rehabilitation). In the primary analysis, we compared IS patients with laboratory-confirmed COVID-19 (IS-COVID) discharged April 1-July 31, 2020 to pre-COVID IS patients discharged in 2019 (IS controls). In a secondary analysis, we compared a matched cohort of IS-COVID patients to patients within the IS controls who had pneumonia (IS-PNA), created with inverse-probability-weighting (IPW). RESULTS: In the primary analysis, we included 166,586 IS controls and 2086 IS-COVID from 312 hospitals in 46 states. Compared to IS controls, IS-COVID were less likely to have hypertension, dyslipidemia, or be smokers, but more likely to be male, younger, have diabetes, obesity, acute renal failure, acute coronary syndrome, venous thromboembolism, intubation, and comorbid intracerebral or subarachnoid hemorrhage (all p<0.05). Black and Hispanic patients accounted for 21.7% and 7.4% of IS controls, respectively, but 33.7% and 18.5% of IS-COVID (p<0.001). IS-COVID, versus IS controls, were less likely to receive alteplase (1.8% vs 5.6%, p<0.001), mechanical thrombectomy (4.4% vs. 6.7%, p<0.001), to have favorable discharge (33.9% vs. 66.4%, p<0.001), but more likely to die (30.4% vs. 6.5%, p<0.001). In the matched cohort of patients with IS-COVID and IS-PNA, IS-COVID had a higher risk of death (IPW-weighted OR 1.56, 95% CI 1.33-1.82) and lower odds of favorable discharge (IPW-weighted OR 0.63, 95% CI 0.54-0.73). CONCLUSIONS: Ischemic stroke patients with COVID-19 are more likely to be male, younger, and Black or Hispanic, with significant increases in morbidity and mortality compared to both ischemic stroke controls from 2019 and to patients with ischemic stroke and pneumonia.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/e4fd984y_hasAnnotation_C0002055> <https://research.tib.eu/covid-19/entity/e4fd984y_hasAnnotation_C0027627> <https://research.tib.eu/covid-19/entity/e4fd984y_hasAnnotation_C0600500> <https://research.tib.eu/covid-19/entity/e4fd984y_hasAnnotation_C1415068> <https://research.tib.eu/covid-19/entity/e4fd984y_hasAnnotation_C1825598>
?:creator	<https://research.tib.eu/covid-19/entity/de_Havenon%2C_Adam%3B_Ney%2C_John_P.%3B_Callaghan%2C_Brian%3B_Delic%2C_Alen%3B_Hohmann%2C_Samuel%3B_Shippey%2C_Ernie%3B_Esper%2C_Gregory_J.%3B_Stulberg%2C_Eric%3B_Tirschwell%2C_David%3B_Frontera%2C_Jennifer%3B_Yaghi%2C_Shadi%3B_Anadani%2C_Mohammad%3B_Majersik%2C_Jennifer_J.>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.jstrokecerebrovasdis.2020.105535>
?:doi	10.1016/j.jstrokecerebrovasdis.2020.105535
?:journal	J_Stroke_Cerebrovasc_Dis
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/8811c4bc1ee730649329f7f749d3893298757b48.json
?:pmc_json_files	document_parses/pmc_json/PMC7832426.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7832426>
?:pmid	<https://research.tib.eu/covid-19/entity/33310595.0>
?:pmid	33310595.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/e4fd984y_HAS_C0020538_AFFECTS_C0948008> <https://research.tib.eu/covid-19/entity/e4fd984y_HAS_C0032143_TREATS_C0948008>
?:sha_id	<https://research.tib.eu/covid-19/entity/8811c4bc1ee730649329f7f749d3893298757b48>
?:source	Elsevier; Medline; PMC
?:title	Impact of COVID-19 on Outcomes in Ischemic Stroke Patients in the United States
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-09

Property

Value

?:abstract

BACKGROUND: Studies have shown worse outcomes in patients with comorbid ischemic stroke (IS) and coronavirus disease 2019 (COVID-19), but have had small sample sizes. METHODS: We retrospectively identified patients in the Vizient Clinical Data Base® with IS as a discharge diagnosis. The study outcomes were in-hospital death and favorable discharge (home or acute rehabilitation). In the primary analysis, we compared IS patients with laboratory-confirmed COVID-19 (IS-COVID) discharged April 1-July 31, 2020 to pre-COVID IS patients discharged in 2019 (IS controls). In a secondary analysis, we compared a matched cohort of IS-COVID patients to patients within the IS controls who had pneumonia (IS-PNA), created with inverse-probability-weighting (IPW). RESULTS: In the primary analysis, we included 166,586 IS controls and 2086 IS-COVID from 312 hospitals in 46 states. Compared to IS controls, IS-COVID were less likely to have hypertension, dyslipidemia, or be smokers, but more likely to be male, younger, have diabetes, obesity, acute renal failure, acute coronary syndrome, venous thromboembolism, intubation, and comorbid intracerebral or subarachnoid hemorrhage (all p<0.05). Black and Hispanic patients accounted for 21.7% and 7.4% of IS controls, respectively, but 33.7% and 18.5% of IS-COVID (p<0.001). IS-COVID, versus IS controls, were less likely to receive alteplase (1.8% vs 5.6%, p<0.001), mechanical thrombectomy (4.4% vs. 6.7%, p<0.001), to have favorable discharge (33.9% vs. 66.4%, p<0.001), but more likely to die (30.4% vs. 6.5%, p<0.001). In the matched cohort of patients with IS-COVID and IS-PNA, IS-COVID had a higher risk of death (IPW-weighted OR 1.56, 95% CI 1.33-1.82) and lower odds of favorable discharge (IPW-weighted OR 0.63, 95% CI 0.54-0.73). CONCLUSIONS: Ischemic stroke patients with COVID-19 are more likely to be male, younger, and Black or Hispanic, with significant increases in morbidity and mortality compared to both ischemic stroke controls from 2019 and to patients with ischemic stroke and pneumonia.

is ?:annotates of